Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.36 |
| ▸ | JUN | P05412 | 2/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.36 |
| ▸ | RELA | Q04206 | 2/20 | 0.36 |
| ▸ | XPO1 | O14980 | 3/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.33 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.33 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | ATF1 | P18846 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090729 | 0.86 | ALDH1A1 (0.49) | ALDH1A1MAPK1SMN1; SMN2NFKB1JUN | |
| SCHEMBL565623 | 0.84 | POLB (0.46) | ALDH1A1MAPK1SMN1; SMN2NFKB1JUN | |
| SCHEMBL29021390 | 0.83 | CA1 (0.35) | ALDH1A1MAPK1SMN1; SMN2NFKB1JUN | |
| SCHEMBL31337111 | 0.83 | CA1 (0.35) | ALDH1A1MAPK1SMN1; SMN2NFKB1JUN | |
| SCHEMBL5871893 | 0.82 | NFKB1 (0.33) | ALDH1A1MAPK1SMN1; SMN2NFKB1JUN | |
| SCHEMBL6357726 | 0.81 | NFKB1 (0.40) | ALDH1A1MAPK1SMN1; SMN2NFKB1JUN | |
| SCHEMBL6882542 | 0.81 | JUN (0.32) | ALDH1A1MAPK1SMN1; SMN2NFKB1JUN | |
| SCHEMBL6357961 | 0.80 | JUN (0.33) | ALDH1A1MAPK1SMN1; SMN2NFKB1JUN | |
| SCHEMBL6357967 | 0.80 | JUN (0.33) | ALDH1A1MAPK1SMN1; SMN2NFKB1JUN | |
| SCHEMBL6357963 | 0.80 | XPO1 (0.33) | ALDH1A1MAPK1SMN1; SMN2NFKB1JUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118206482-B | Synthesis method of 4-trifluoromethyl nicotinamide | 山东京博生物科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-118206482-A | Synthesis method of 4-trifluoromethyl nicotinamide | 山东京博生物科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-8143411-B2 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | BAYER ANIMAL HEALTH GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-7109196-B2 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060189609-A1 | 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-24 | — | — | US | disclosed |
| US-6964971-B2 | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-15 | — | — | US | disclosed |
| WO-2005091857-A2 | 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE DERIVATIVES AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005091857-A2 | 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE DERIVATIVES AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| US-6900205-B2 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040014751-A1 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-6677352-B1 | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-01-13 | — | — | US | disclosed |
| WO-2003027113-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027112-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027112-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-0787726-B1 | NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-11-28 | — | — | EP | disclosed |
| CN-1053668-C | Novel compound, process for producing the same, and antitumor agent | DAINIPPON PHARMACEUTICAL CO (JP) | 2000-06-21 | — | — | CN | disclosed |
| US-5817669-A | A COMPOUND CONTAINING 1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| CN-1158614-A | Novel compound, process for producing the same, and antitumor agent | DAINIPPON PHARMACEUTICAL CO (JP) | 1997-09-03 | — | — | CN | disclosed |
| EP-0787726-A1 | NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014751-A1 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | UQCRC1, GLP1R, SLC5A1 | ALDH1A1 820/4885MAPK1 1071/4885SMN1; SMN2 3159/4885 |
| US-20100234432-A1 | Substituted 6-phenylnicotinic acids and their use | SLC5A6, FABP3, NAPRT | ALDH1A1 1238/4885MAPK1 1221/4885SMN1; SMN2 2562/4885 |
| US-20060189609-A1 | 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders | GLP1R, UQCRC1, SLC5A1 | ALDH1A1 1148/4885MAPK1 1389/4885SMN1; SMN2 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.